Endothelium

Stimulating blood vessel formation with magnets

Wednesday, July 21, 2021 - 11:00pm

This was used to treat endothelial cells, stimulating blood vessel formation.

Key Points: 
  • This was used to treat endothelial cells, stimulating blood vessel formation.
  • "We developed a promising cell therapy alternative that can non-invasively stimulate blood vessel formation or regeneration through the application of an external low-intensity magnetic field."
  • These cells can change into different cell types, and also secrete a protein called VEGF-A that stimulates blood vessel formation.
  • Finally, VEGF-A extracts produced by magnet-treated mesenchymal stromal cells on gelatin increased blood vessel formation in a chick embryo, although further research is needed to confirm these results.

Petros Pharmaceuticals to Present at the Access to Giving Virtual Investor Conference on July 14, 2021

Monday, July 12, 2021 - 1:15pm

NEW YORK, July 12, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 15, 2021.

Key Points: 
  • NEW YORK, July 12, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the Access to Giving Virtual Investor Conference being held July 13 15, 2021.
  • Mr. Boctor will deliver his corporate presentation on July 14 at 3:30pm ET.
  • To receive additional information, request an invitation or to schedule a one-on-one meeting, please email angie.goertz@issuerdirect.com .
  • Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.

EyeYon Medical Receives CE Mark for its EndoArt® Implant to Treat Chronic Corneal Edema

Tuesday, June 8, 2021 - 1:30pm

This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue.

Key Points: 
  • This unique implant enables doctors to treat endothelial-related chronic corneal edema with a minimally invasive surgery that erodes the use of human tissue.
  • The EndoArt is designed to replace dysfunctional endothelium in patients awaiting human donor tissue as a first-line treatment for patients with chronic corneal edema.
  • "We are proud to receive CE mark for our unique EndoArt implant which is set to transform the way patients with chronic corneal edema are treated," said Nahum Ferera, Co-Founder and CEO of EyeYon Medical.
  • EyeYon Medical's flagship product is an Artificial Endothelial Layer - EndoArt, a synthetic implant, attached to the posterior corneal surface to treat chronic corneal edema secondary to endothelial dysfunction.

Petros Pharmaceuticals to Present at the LD Micro Virtual Invitational Conference on June 10, 2021

Wednesday, June 2, 2021 - 3:12pm

NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.

Key Points: 
  • NEW YORK, June 2, 2021 /PRNewswire/ -- Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that President and Chief Commercial Officer Fady Boctor will present a corporate overview at the three-day LD Micro Virtual Invitational Conference being held on June 8 10, 2021.
  • Mr. Boctor will deliver his corporate presentation on June 10 at 4:00pm ET, Track 1.
  • Petros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.

Petros Pharmaceuticals to Participate at the Investor Summit Conference and Present to Investors on May 18, 2021

Friday, May 14, 2021 - 1:30pm

b"NEW YORK, May 14, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nPresident and Chief Commercial Officer Fady Boctor will deliver his corporate presentation at 9:30am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with Mr. Boctor to be arranged following the conclusion of the conference.\nPetros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.\n"

Key Points: 
  • b"NEW YORK, May 14, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Investor Summit Conference on May 18, 2021.\nPresident and Chief Commercial Officer Fady Boctor will deliver his corporate presentation at 9:30am ET on May 18, 2021.\nInvestors can also request a one-on-one meeting with Mr. Boctor to be arranged following the conclusion of the conference.\nPetros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.\n"

Arctic Vision announces exclusive licensing agreement with ActualEyes

Friday, May 14, 2021 - 1:00pm

Studies[i],[ii] have demonstrated that the injection of hCECs supplemented with a ROCK inhibitor has positive efficacy and safety profiles in patients with corneal endothelial dysfunction.

Key Points: 
  • Studies[i],[ii] have demonstrated that the injection of hCECs supplemented with a ROCK inhibitor has positive efficacy and safety profiles in patients with corneal endothelial dysfunction.
  • Eddy (Hoi Ti) Wu, Founder and CEO, Board Director of Arctic Vision, commented, "We are excited to enter into this partnership with ActualEyes to further develop AE-101, a potent cell-therapy solution for the treatment of corneal endothelial dysfunction.
  • "\nIku Sugioka, President and Chief Executive Officer of ActualEyes, said, "We look forward to collaborating with Arctic Vision to develop our lead clinical candidate AE-101.
  • The company\'s vision is to address ophthalmology\'s unmet needs through innovative therapies in China, Asia and globally.

Petros Pharmaceuticals to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021

Friday, May 7, 2021 - 1:00pm

b"NEW YORK, May 7, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Benzinga Global Small Cap Conference on May 13, 2021.\nPresident and Chief Commercial Officer Fady Boctor will deliver his corporate presentation at 10:50am ET on May 13, 2021.\nInvestors can also request a one-on-one meeting with Mr. Boctor to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nPetros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.\n"

Key Points: 
  • b"NEW YORK, May 7, 2021 /PRNewswire/ --Petros Pharmaceuticals, Inc. (Nasdaq: PTPI), a leading provider of therapeutics for men's health, today announced that management will participate at the Benzinga Global Small Cap Conference on May 13, 2021.\nPresident and Chief Commercial Officer Fady Boctor will deliver his corporate presentation at 10:50am ET on May 13, 2021.\nInvestors can also request a one-on-one meeting with Mr. Boctor to be arranged following the conclusion of the conference.\nInvestors can register for the conference here:\nPetros Pharmaceuticals is committed to the goal of becoming a world-leading specialized men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to erectile dysfunction, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease, hormone health and substance use disorders.\n"

Ocugen Presents New Preclinical OCU200 Data at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting

Thursday, May 6, 2021 - 12:30pm

The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.

Key Points: 
  • The purpose of this study was to evaluate efficacy of OCU200 in in-vitro and in-vivo models for ocular neovascular diseases.
  • Most approved therapeutics target vascular endothelial growth factor (VEGF), a pro-angiogenic factor with neurotrophic and neuroprotective effects.
  • However, approximately 50% of Patients do not respond to anti-VEGF/Corticosteroids therapies.\nOCU200 inhibited cell proliferation, cell invasion and tube formation by endothelial cells.
  • Arun Upadhyay, VP and Head of R&D, Ocugen Inc.\n'

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2® to Treat ARDS Resulting from COVID-19 Infection

Thursday, May 6, 2021 - 12:30pm

The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.

Key Points: 
  • The SVF derived from the Icellator2 contains a population of mesenchymal stem cells, vascular endothelial cells, and immune cells which migrate to the patient\xe2\x80\x99s lungs and other peripheral sites of inflammation.
  • Orgenesis believes the multiple mechanisms of action of the SVF derived from the Icellator2 are important to treat ARDS and other inflammatory disorders.\nThe FDA IDE approval covers 21 patients at one clinical site in the United States.
  • We are excited to move forward with clinical development of the Icellator to treat ARDS, COVID-19-related complications, and other serious conditions.
  • Our interactions with the FDA through the IDE process will inform our development plans.

The NOSTRADAMUS Study: Microvascular Dysfunction in Sepsis

Monday, April 19, 2021 - 6:00pm

The study, titled "Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study" was published in Critical Care.

Key Points: 
  • The study, titled "Identification of novel sublingual parameters to analyze and diagnose microvascular dysfunction in sepsis: the NOSTRADAMUS study" was published in Critical Care.
  • "For several years, GlycoCheck has been used globally in groundbreaking research to understand the complex nature of the endothelial glycocalyx.
  • "\nThe study concludes that new important diameter-specific quantification and differentiated analysis of RBC kinetics is a key to understand microvascular dysfunction in sepsis.
  • MVHSdynamic, which has a broad bandwidth to detect micro-vascular (dys-) function, might serve as a valuable tool to detect microvascular impairment in critically ill patients.\nGlycoCheck analyzes glycocalyx, endothelium, and capillary function.